ArticleAmerican journal of translational research2023
Efficacy of laser photocoagulation plus ranibizumab in patients with diabetic retinopathy and their effect on VEGF.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Narrative review of comprehensive management strategies for diabetic retinopathy: interdisciplinary approaches and future perspectives.BMJ public health · 2025Review
- Injectable, reversibly thermoresponsive captopril-laden hydrogel for the local treatment of sensory loss in diabetic neuropathy.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the efficacy of laser photocoagulation combined with ranibizumab in patients with diabetic retinopathy and their effect on VEGF.
methodsThe medical records of 98 patients with diabetic retinopathy treated in the First People's Hospital of Linping District from February 2020 to January 2022 were collected for a retrospective analysis. Among them, 48 patients treated with laser photocoagulation were a control group (CG), and another 50 treated with laser photocoagulation combined with ranibizumab were an observation group (OG). The treatment efficacy, best corrected visual acuity (BCVA), central macular concave thickness (CMT), and change in neovascularization area were compared between the two groups. Also, the changes in serum vascular endothelial growth factor (VEGF), homocysteine (HCY), vitamin B12 and folic acid were compared. The adverse effects that occurred with treatment were assessed. The relationship of pre-treatment BCVA, CMT, neovascularization area and VEGF levels with clinical outcomes were observed, and their predictive values were analyzed by receiver operating characteristic (ROC) curve.
resultsThe total response rate of patients in the CG was lower than that in the OG (P<0.05). The BCVA, CMT, and neovascularization area were dramatically lower, while vitamin B12 and folic acid were markedly higher in the OG than in the CG after treatment (P<0.05). There was no statistical difference in adverse reactions between the two groups (P>0.05). In patients with effective response, the BCVA, CMT, VEGF and Hcy before treatment were dramatically lower than in those with ineffective response (P<0.05), while the neovascularization area, vitamin B12, and folic acid did not differ between them before treatment (P>0.05). ROC curve analysis revealed that the areas under the curve of BCVA, CMT, VEGF and Hcy were all greater than 0.7 for predicting patient outcomes, and the area under the curve of the combination of the above indexes was 0.945, with a specificity of 92.30% and sensitivity of 88.23%.
conclusionLaser photocoagulation combined with ranibizumab may provide good therapeutic efficacy in diabetic retinopathy, by effectively improving neovascularization and reducing VEGF levels to control further progression of the lesions.
Indexed as
Identifiers
36777841PMC9908459What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.